Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$4.63 USD
-0.04 (-0.86%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $4.63 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AUTL 4.63 -0.04(-0.86%)
Will AUTL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUTL
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
AUTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Other News for AUTL
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Oxford Biomedica announces CFO transition
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
Buy Rating Affirmed for Autolus Therapeutics Amid Promising Clinical Data and Advancements in Treatment Monitoring